Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies

T cells modified via chimeric antigen receptors (CARs) have emerged as a promising treatment modality. Unparalleled clinical efficacy recently demonstrated in refractory B-cell malignancy has brought this new form of adoptive immunotherapy to the center stage. Nonetheless, its current success has al...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Shangjun, Hao, He, Yang, Ge, Zhang, Yi, Fu, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932485/
https://www.ncbi.nlm.nih.gov/pubmed/29850622
http://dx.doi.org/10.1155/2018/2386187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932485/
https://www.ncbi.nlm.nih.gov/pubmed/29850622
http://dx.doi.org/10.1155/2018/2386187

Ejemplares similares